Related Experiment Video

Updated: May 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate

Liliana Grigore1, Sara Raselli, Katia Garlaschelli

  • 1Center for the Study of Atherosclerosis-SISA Lombardia, Bassini Hospital, Via Gorki 50, 20092 Cinisello Balsamo, Milan, Italy.

European Journal of Clinical Pharmacology
|July 11, 2012
PubMed

Insights

Both pravastatin and ezetimibe improved endothelial function similarly in hypercholesterolemic patients. This suggests cholesterol reduction, not pleiotropic effects, drives statin benefits on vascular health.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Vascular Biology

Background:

  • Statins improve endothelial function, but whether this is due to lipid-lowering or pleiotropic effects is debated.
  • Investigating the mechanisms behind statin-induced improvements in endothelial function is crucial for understanding cardiovascular health.
  • Understanding the specific contributions of lipid reduction versus pleiotropic effects is key to optimizing cardiovascular therapies.

Purpose of the Study:

  • To determine if pravastatin's effect on endothelial function is mediated by pleiotropic effects.
  • To compare the impact of pravastatin and ezetimibe on endothelial function (flow-mediated dilation).
  • To investigate whether similar reductions in low-density lipoprotein cholesterol (LDL-C) by different mechanisms yield comparable improvements in endothelial function.

Main Methods:

  • Randomized controlled trial involving 33 hypercholesterolemic patients.
  • Treatment groups: ezetimibe 10 mg/day, pravastatin 10 mg/day, or no treatment (control) for 6 weeks.
  • Endothelial function assessed non-invasively using high-resolution ultrasound to measure brachial artery flow-mediated dilation (FMD) before and after treatment.

Main Results:

  • Both ezetimibe and pravastatin significantly reduced LDL-C by approximately 20-24% without significant difference between groups.
  • Flow-mediated dilation (FMD) significantly increased in both ezetimibe and pravastatin groups post-treatment.
  • No significant difference in the improvement of endothelial function was observed between the pravastatin and ezetimibe treatment groups.

Conclusions:

  • Cholesterol-lowering treatments, ezetimibe and pravastatin, improved endothelial function to a similar extent.
  • The findings suggest that the improvement in endothelial function observed with pravastatin can be attributed to its cholesterol-lowering effects.
  • This study supports the hypothesis that significant LDL-C reduction, rather than pleiotropic effects alone, is the primary driver of improved endothelial function in this context.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...